The Cleveland Clinic Foundation

The Cleveland Clinic Foundation Finance / Academic Affairs Fiscal Services Division, operating as Cleveland Clinic Health System and its subsidiaries, is a non-profit academic medical center headquartered in Cleveland, Ohio, that delivers clinical laboratory services, medical research support, and healthcare innovation to the federal government as a prime contractor (83% of recent awards) and grant recipient across civilian and military health agencies. The organization competes on a full-and-open basis with no SBA set-asides and operates across a nationwide footprint with performance at multiple locations including Cleveland, Ohio; Seattle, Washington; and other regional and specialty care sites.

Cleveland Clinic's federal contract work centers on clinical laboratory and diagnostic support services delivered primarily to the Department of Veterans Affairs through a $2.5 million single-award indefinite-delivery contract with Veterans Integrated Service Network (VISN) 10 running through May 31, 2028. Under this vehicle, the organization delivers anatomic referral laboratory services and laboratory testing capabilities to support the Cleveland VA Medical Center; recent delivery orders include $1.37 million for anatomic referral laboratory services (awarded June 11, 2025) and $701 thousand for the second ordering period (awarded September 8, 2024). Beyond VA work, Cleveland Clinic holds smaller purchase orders from VA VISN 20 for biorobotics lab software support ($15 thousand, awarded August 15, 2025) and expert witness services from the U.S. Attorney's Offices ($4 thousand, awarded August 14, 2024).

Federal grant work substantially outweighs contract activity by both volume and dollar magnitude. The Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is the dominant funding source, with the organization serving as prime recipient on approximately 70 grants across oncology, neuroscience, immunology, and translational medicine research. Representative grants include $1.12 million for biocompatible graphene quantum dots for melanoma prevention (awarded November 1, 2026), $1.28 million for kidney cancer amino acid transporter research (awarded September 1, 2025), $1.92 million for spinal cord injury biomarker development (awarded July 1, 2025), and $999 thousand for multiple sclerosis transcriptomic analysis (awarded November 1, 2025). The Advanced Research Projects Agency for Health awarded a $2.73 million cooperative agreement (August 20, 2025) to develop wearable eTattoo cardiac monitoring technology for congenital heart disease patients, with sub-awardees at the University of Texas at Austin, Georgia Tech Research Corp, and UT Southwestern Medical Center managing device design, algorithm development, and patient recruitment. The National Science Foundation awarded $999 thousand under the Biological Sciences program (CFDA 47.074) for telomere end-protection research (awarded September 1, 2025) and $289 thousand for open-source ecosystem planning for knee biomechanics research (awarded June 15, 2024). The Department of Health and Human Services Administration for Community Living awarded $748 thousand under the Alzheimer's Disease Program Initiative (CFDA 93.470) for the Cleveland Clinic Nevada Dementia Education and Empowerment Initiative (awarded September 1, 2024), and the Health Resources and Services Administration awarded a $1.92 million grant for Sexual Assault Nurse Examiner training (awarded July 1, 2024).

Customer concentration is high in research funding. The Defense Health Agency leads by award count (93 awards, $8 thousand combined potential value — a placeholder artifact) and holds substantial influence through the Military Medical Research and Development program portfolio. The Department of Veterans Affairs VISN 10 ranks second (30 awards, $9 million combined potential value) driven by the anatomic referral laboratory contract. By dollar magnitude, the National Institutes of Health National Cancer Institute tops the ranking ($11.3 million across 13 awards), followed by VA VISN 10 ($9 million) and the National Heart Lung and Blood Institute ($4.8 million). Recent activity shows growth from 2022 through 2024 (16 awards in 2022 to 41 in 2024) with a slight contraction in 2025 and early 2026 (35 and 18 awards respectively). Twenty-three awards (combined potential value $1 million) face ultimate completion within the next twenty-four months and represent recompete exposure.

Cleveland Clinic operates as a subcontractor on federal grants to lead universities and research institutions. Named prime grantees include the University of Texas at Austin (cardiac monitoring device development), the Johns Hopkins University (multiple clinical trial consortia including BEACH and DRIVE-USA), Stanford University (non-compaction cardiomyopathy imaging research), Harvard Medical School (iron regulation in pediatric HIV), the University of Pennsylvania (flow cytometry methods development), and Vanderbilt University Medical Center (kidney cancer investigator networks and respiratory virus surveillance). Cleveland Clinic contributes specialized expertise in clinical trial execution, data analysis, biospecimen management, and translational research infrastructure across these partnerships.

The organization's federal footprint spans 71 customer agencies across cabinet departments and independent agencies. Beyond the concentrated VA and NIH relationships, significant activity flows from the Department of Defense (via the Defense Health Agency), the National Aeronautics and Space Administration Glenn Research Center (11 awards, $1.8 million), the Department of State Bureau of Medical Services (6 awards, $1.8 million), and various state and local health agencies receiving federally passed-through funding. Service Contract Inventory reporting shows minimal SCI-reportable invoiced revenue on federal prime contracts (zero dollars across FY2022–FY2025) with 8.2 FTEs delivered in FY2024 and 6.1 FTEs in FY2025, reflecting that much of Cleveland Clinic's federal activity falls outside the $150 thousand SCI reporting threshold or is classified as research rather than service delivery.

Corporate structure comprises four named subsidiaries: the Lou Ruvo Brain Institute, The Cleveland Clinic, the Cleveland Clinic Foundation, and Akron General Medical Center, each carrying capability signals in their names. The organization leverages this structure to deliver specialized services — neuroscience research through the Lou Ruvo Center, regional care through Akron General — while maintaining unified federal contracting posture through its parent Finance / Academic Affairs Fiscal Services Division.